APA (7th ed.) Citation

L, G., J, X., J, H., S, S., M, D., A, Z., . . . SP, C. (2023). Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. Frontiers in oncology, 13, 1289249. https://doi.org/10.3389/fonc.2023.1289249

Chicago Style (17th ed.) Citation

L, Gallagher, et al. "Early Biochemical Outcomes Following Neoadjuvant/adjuvant Relugolix with Stereotactic Body Radiation Therapy for Intermediate to High Risk Prostate Cancer." Frontiers in Oncology 13 (2023): 1289249. https://doi.org/10.3389/fonc.2023.1289249.

MLA (9th ed.) Citation

L, Gallagher, et al. "Early Biochemical Outcomes Following Neoadjuvant/adjuvant Relugolix with Stereotactic Body Radiation Therapy for Intermediate to High Risk Prostate Cancer." Frontiers in Oncology, vol. 13, 2023, p. 1289249, https://doi.org/10.3389/fonc.2023.1289249.